SG Americas Securities
SLN

SG Americas Securities’s Silence Therapeutics SLN Stock Holding History

SG Americas Securities’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.51M Buy
286,698
+30,358
+12% +$167K ﹤0.01% 1527
2025
Q4 		$1.56M Sell
256,340
-51,949
-17% -$333K ﹤0.01% 1690
2025
Q3 		$1.6M Sell
308,289
-42
-0% -$233 0.01% 1091
2025
Q2 		$1.79M Buy
308,331
+42
+0% +$180 0.01% 831
2025
Q1 		$869K Sell
308,289
-9,339
-3% -$45.6K ﹤0.01% 1290
2024
Q4 		$2.19M Sell
317,628
-25,562
-7% -$330K 0.01% 572
2024
Q3 		$6.24M Sell
343,190
-6
-0% -$112 0.02% 352
2024
Q2 		$6.52M Buy
343,196
+336,196
+4,803% +$7.15M 0.04% 445
2024
Q1 		$151K Buy
7,000
+667
+11% +$14.5K ﹤0.01% 2201
2023
Q4 		$110K Buy
+6,333
New +$71.1K ﹤0.01% 2694
2023
Q1 		– Sell
-87,987
Closed -$1.34M – 3524
2022
Q4 		$1.34M Sell
87,987
-10,966
-11% -$144K 0.02% 782
2022
Q3 		$977K Sell
98,953
-2,500
-2% -$26.3K 0.01% 1033
2022
Q2 		$1.2M Buy
101,453
+8
+0% +$97 0.01% 1135
2022
Q1 		$1.93M Sell
101,445
-400
-0.4% -$7.97K 0.01% 942
2021
Q4 		$2.38M Buy
101,845
+89,143
+702% +$2.06M 0.01% 950
2021
Q3 		$275K Buy
12,702
+7,300
+135% +$174K ﹤0.01% 3005
2021
Q2 		$138K Sell
5,402
-43
-0.8% -$1.12K ﹤0.01% 2503
2021
Q1 		$129K Buy
+5,445
New +$132K ﹤0.01% 2945

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

SG Americas Securities's SLN Position: Q1 2026 in Review

SG Americas Securities increased its Silence Therapeutics (SLN) stake by 12% in Q1 2026, buying an estimated $167K and bringing the position to 286,698 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #1527.

SG Americas Securities first reported a position in SLN in Q1 2021 and has held it in 18 quarters since. The position peaked at $6.52M in Q2 2024. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • SG Americas Securities held 286,698 shares of Silence Therapeutics worth $1.51M as of Q1 2026.
  • SG Americas Securities bought 30,358 Silence Therapeutics shares in Q1 2026, an estimated $167K.
  • Silence Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #1527 holding.
  • SG Americas Securities first reported a position in Silence Therapeutics in Q1 2021 and has held it in 18 quarters since.
  • SG Americas Securities's Silence Therapeutics position peaked at $6.52M in Q2 2024.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.